BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21266362)

  • 1. Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth.
    Smith BH; Gazda LS; Conn BL; Jain K; Asina S; Levine DM; Parker TS; Laramore MA; Martis PC; Vinerean HV; David EM; Qiu S; North AJ; Couto CG; Post GS; Waters DJ; Cordon-Cardo C; Hall RD; Gordon BR; Diehl CH; Stenzel KH; Rubin AL
    Cancer Res; 2011 Feb; 71(3):725-35. PubMed ID: 21266362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties.
    Smith BH; Gazda LS; Conn BL; Jain K; Asina S; Levine DM; Parker TS; Laramore MA; Martis PC; Vinerean HV; David EM; Qiu S; Cordon-Cardo C; Hall RD; Gordon BR; Diehl CH; Stenzel KH; Rubin AL
    Cancer Res; 2011 Feb; 71(3):716-24. PubMed ID: 21266363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEF2 plays a significant role in the tumor inhibitory mechanism of encapsulated RENCA cells via EGF receptor signaling in target tumor cells.
    Martis PC; Dudley AT; Bemrose MA; Gazda HL; Smith BH; Gazda LS
    BMC Cancer; 2018 Dec; 18(1):1217. PubMed ID: 30514247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
    Ogushi T; Takahashi S; Takeuchi T; Urano T; Horie-Inoue K; Kumagai J; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
    Cancer Res; 2005 May; 65(9):3700-6. PubMed ID: 15867365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential.
    Miyake H; Hara I; Yoshimura K; Eto H; Arakawa S; Wada S; Chihara K; Kamidono S
    Cancer Res; 1996 May; 56(10):2440-5. PubMed ID: 8625325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential.
    Miyake H; Hara I; Gohji K; Yamanaka K; Hara S; Arakawa S; Nakajima M; Kamidono S
    Clin Cancer Res; 1999 Oct; 5(10):2824-9. PubMed ID: 10537348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability.
    Gazda LS; Martis PC; Laramore MA; Bautista MA; Dudley A; Vinerean HV; Smith BH
    Cancer Biol Ther; 2013 Dec; 14(12):1147-57. PubMed ID: 24025409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
    Perry K; Wong L; Liu V; Park I; Zhang Q; Rejen V; Huang X; Smith ND; Jovanovic B; Lonning S; Teicher BA; Lee C
    Urology; 2008 Jul; 72(1):225-9. PubMed ID: 18295867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
    Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
    Seki N; Hayakawa Y; Brooks AD; Wine J; Wiltrout RH; Yagita H; Tanner JE; Smyth MJ; Sayers TJ
    Cancer Res; 2003 Jan; 63(1):207-13. PubMed ID: 12517799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
    Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
    Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ki-67 antisense therapy in murine renal cell carcinoma models].
    Kausch I; Jiang H; Brocks C; Albers A; Krüger S; Sczakiel G; Jocham D
    Aktuelle Urol; 2005 Apr; 36(2):142-8. PubMed ID: 15902575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors.
    Krneta J; Kroll J; Alves F; Prahst C; Sananbenesi F; Dullin C; Kimmina S; Phillips DJ; Augustin HG
    Cancer Res; 2006 Jun; 66(11):5686-95. PubMed ID: 16740706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.